Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.

ABSTRACT:

Background

Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that is used off-label for select cases of recurrent respiratory papillomatosis (RRP) that are severe, involve the distal airway or lung parenchyma, and refractory to other forms of adjuvant therapy. However, there is limited safety data for the use of bevacizumab in children and VEGF inhibitors are reported to have a range of adverse renal effects, including hypertension, proteinuria, and thrombotic microangiopathy (TMA).

Case-diagnosis/treatment

This report describes a case of severe juvenile-onset RRP that had an exceptionally high operative burden that was refractory to several adjuvant treatment strategies (including intralesional cidofovir and subcutaneous pegylated interferon). Bevacizumab

SUBMITTER: Robinson CH 

PROVIDER: S-EPMC10759239 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature